Technology ID
TAB-4858
Highly Potent Monoclonal Antibodies Targeting CSP
E-Numbers
E-038-2017-0
Lead Inventor
Flynn, Barbara
Lead IC
NIAID
Co-Inventors
Seder, Robert
Kisalu, Neville
Idris, Azza
Hoffman, Stephen
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Clinical Phase II
Research Products
Research Equipment
Antibodies
Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions. Clinical trials are on the horizon to assess their efficacy and safety in humans, marking a critical step towards eradicating this deadly disease.
Commercial Applications
These CSP-targeting monoclonal antibodies have wide-ranging potential applications. They can be instrumental in preventing malaria for travelers, military personnel, and diplomats in endemic regions. Additionally, their efficacy makes them a valuable tool for malaria eradication efforts among residents and healthcare workers in these regions. Moreover, their versatility extends to potentially targeting other parasite surface immunogens, offering a broader scope for malaria prevention strategies. In summary, these antibodies have the potential to revolutionize malaria control efforts and bring us closer to a malaria-free world.
Competitive Advantages
Monoclonal antibodies (mAbs) targeting CSP for malaria prevention possess a significant competitive edge due to their exceptional 100-fold potency increase compared to existing mouse monoclonal CSP antibodies. These fully human recombinant mAbs are poised for clinical trials, offering a potent and advanced solution with the potential to reshape malaria prevention strategies. Their capacity to target additional parasite surface immunogens further enhances their versatility, establishing them as leaders in the fight against malaria.
Licensing Contact: